Mayo Clinic is expanding its clinical territory into drug discovery and development for the first time by partnering with artificial intelligence (AI) firm Nference to create Qrativ. Virtual for now, the startup plans to forge collaborations with third parties and to in-license drug candidates – either way, applying a data-driven approach that combines a range of AI techniques.